Elekta looks after shareholders in rare Swedish CB
Elekta, the Swedish neuroscience and cancer treatment company, set out plans this week to raise Skr1.9bn (€214m) from a convertible bond in a rare equity-linked deal from the country. It will use a pre-emptive structure, complete with a discounted issue price and tradable subscription rights, to tackle Swedish cultural antipathy to the CB market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts